Paper42731007
[Anthracycline use in breast cancer based on our current knowledge].
Rubovszky G and 2 others. Magy Onkol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. [Anthracycline use in breast cancer based on our current knowledge]. Papers, record 42731007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42731007
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Anthracyclines | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Antineoplastic Agents | Major topic |
| Antibiotics, Antineoplastic | Major topic |
| Humans | |
| Female | |
| Treatment Outcome | |
| Erb-b2 Receptor Tyrosine Kinases | |
| Chemotherapy, Adjuvant |
Source PubMed
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1462166 | The anthracyclines: will we ever find a better doxorubicin? | Semin Oncol | 1992 | https://conductscience.org/library/papers/1462166 | PubMed |
| 2 | 39396348 | Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials. | Lancet | 2024 | https://conductscience.org/library/papers/39396348 | PubMed |
| 3 | 30739743 | Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. | Lancet | 2019 | https://conductscience.org/library/papers/30739743 | PubMed |
| 4 | 32258060 | Cardiotoxicity of Anthracyclines. | Front Cardiovasc Med | 2020 | https://conductscience.org/library/papers/32258060 | PubMed |
| 5 | 17135639 | Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/17135639 | PubMed |
| 6 | 36858723 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/36858723 | PubMed |
| 7 | 22392196 | Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis. | Med Oncol | 2012 | https://conductscience.org/library/papers/22392196 | PubMed |
| 8 | 40618711 | Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer: A non-inferiority meta-analysis. | Breast | 2025 | https://conductscience.org/library/papers/40618711 | PubMed |
| 9 | 21681601 | Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy. | Pathol Oncol Res | 2012 | https://conductscience.org/library/papers/21681601 | PubMed |
| 10 | 22152853 | Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. | Lancet | 2012 | https://conductscience.org/library/papers/22152853 | PubMed |
| 11 | 38173817 | Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention. | Front Cardiovasc Med | 2023 | https://conductscience.org/library/papers/38173817 | PubMed |
| 12 | 29236294 | Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. | Cancer | 2018 | https://conductscience.org/library/papers/29236294 | PubMed |
| 13 | 28398846 | Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28398846 | PubMed |
| 14 | 38335467 | Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38335467 | PubMed |
| 15 | 21917518 | HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. | Lancet Oncol | 2011 | https://conductscience.org/library/papers/21917518 | PubMed |
| 16 | 39556787 | Pregnancy-Associated Breast Cancer: Key Concepts for Optimizing Diagnosis and Treatment. | JCO Oncol Pract | 2025 | https://conductscience.org/library/papers/39556787 | PubMed |
| 17 | 41436191 | Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial. | BMJ | 2025 | https://conductscience.org/library/papers/41436191 | PubMed |
| 18 | 39479333 | Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review. | JACC CardioOncol | 2024 | https://conductscience.org/library/papers/39479333 | PubMed |
| 19 | 31289672 | Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment. | Mol Clin Oncol | 2019 | https://conductscience.org/library/papers/31289672 | PubMed |
| 20 | 39143082 | Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer. | NPJ Breast Cancer | 2024 | https://conductscience.org/library/papers/39143082 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42731007
GET https://conductscience.org/api/papers/v1/42731007/references?page=2